

Ref No.: ZLL/CS/BM/BSE-NSE

Date: 07.08.2025

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code - 541400)	National Stock Exchange of India Limited, Listing Compliance Department, Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
--	---

Dear Sir,

Sub : **Outcome of Board Meeting held on 07.08.2025**

Ref : **Intimation of Board Meeting dt. 31.07.2025**

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved:

- 1) The Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2025.

Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Deloitte Haskins & Sells LLP, Statutory Auditors of the Company is enclosed herewith.

- 2) Appointment of Protiviti India Member Private Limited as Internal Auditors of the Company for the F.Y. 2025-26.
- 3) Investment of up to AED 4,50,000 in the share capital of ZIM Scientific Office L.L.C., Step-down Subsidiary of the Company by ZIM Laboratories Limited FZE, Wholly Owned Subsidiary of the Company.
- 4) Closure of ZIM Laboratories Middle East DMCC, Step Down Subsidiary of the Company.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CI R/2023/123 dated July 13, 2023 are enclosed as Annexure I, II & III.

ZIM LABORATORIES LIMITED

Kindly take the intimation on record.

The Board Meeting commenced at 12:30 p.m (IST) and concluded at 7:00 p.m (IST)

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl: as above

ZIM LABORATORIES LIMITED

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

**TO THE BOARD OF DIRECTORS OF
ZIM LABORATORIES LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **ZIM LABORATORIES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:

Name of the Company	Relationship
ZIM Laboratories FZE, Sharjah	Subsidiary Company
ZIM Health Technologies Limited, India	Subsidiary Company
SIA ZIM Laboratories Limited, Latvia	Subsidiary Company
ZIM Thinorals Private Limited, India	Subsidiary Company
ZIMTAS PTY Limited, Australia	Subsidiary Company
ZIM Laboratories Middle East DMCC, Dubai	Step-Down Subsidiary
ZIM Scientific Office LLC, Dubai	Step-Down Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Deloitte
Haskins & Sells LLP**

6. The consolidated financial results of the Company for the quarter and year ended March 31, 2025 and the quarter ended June 30, 2024 included in the Statement, were reviewed/audited by another auditor who expressed an unmodified conclusion/opinion on those statements on May 20, 2025 for the quarter and year ended March 31, 2025 and August 3, 2024 for the quarter ended June 30, 2024.

Our conclusion on the statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Viral
Rajnikant
Shah



Digitally signed
by Viral
Rajnikant Shah
Date: 2025.08.07
13:57:28 +05'30'

Viral R. Shah

Partner

Membership No. 117654
UDIN:25117654BMLLN18764

Place: Nagpur
Date: August 7, 2025



Zeal & Innovation in Medicine

ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India

CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2025

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		(Unaudited)	(Unaudited) Refer Note 3 & 4	(Unaudited) Refer Note 4	(Audited) Refer Note 4
1	Income				
	a) Revenue from operations	7,175.61	10,873.30	8,182.44	37,903.10
	b) Other income	147.63	170.98	99.89	578.41
	Total income	7,323.24	11,044.28	8,282.33	38,481.51
2	Expenses				
	a) Cost of materials consumed	2,761.73	4,860.09	3,100.93	15,500.40
	b) Purchases of stock-in-trade	159.30	329.59	265.74	1,157.82
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	79.86	(364.14)	256.40	126.65
	d) Employee benefits	1,461.27	1,632.46	1,450.92	6,075.98
	e) Finance costs	330.35	290.92	285.85	1,138.82
	f) Depreciation and amortisation	486.35	528.90	494.28	2,011.34
	g) Other expenses	2,287.58	2,955.62	2,304.77	10,669.56
	Total expenses	7,566.44	10,233.44	8,158.89	36,680.57
3	Profit /(loss) before tax (1-2)	(243.20)	810.84	123.44	1,800.94
4	Tax expense				
	Current Tax	8.72	340.33	27.62	467.41
	Deferred Tax	(64.43)	(17.94)	5.99	117.03
	Total tax expense	(55.71)	322.39	33.61	584.44
5	Profit /(loss) after tax (3-4)	(187.49)	488.45	89.83	1,216.50
6	Other comprehensive income - profit/(loss)				
	a) Items that will not be reclassified to profit or loss	(18.99)	(35.54)	(13.47)	(75.95)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	5.53	10.35	3.92	22.11
	c) Items that may be reclassified to profit or loss	55.35	(14.05)	2.50	51.09
	d) Tax (expense)/credit on the items that will be reclassified to profit or loss	-	-	-	-
	Other comprehensive income (net of tax) - profit/(loss)	41.89	(39.24)	(7.05)	(2.75)
7	Total comprehensive income (5+6)	(145.60)	449.21	82.78	1,213.75
8	Net Profit after tax attributable to				
	Owners	(187.49)	488.47	89.83	1,216.52
	Non-controlling interest	-	(0.02)	(0.00)	(0.02)
9	Other comprehensive Income attributable to				
	Owners	41.89	(39.24)	(7.05)	(2.75)
	Non-controlling interest	-	-	(0.00)	-
10	Total Comprehensive Income attributable to				
	Owners	(145.60)	449.23	82.78	1,213.77
	Non-controlling interest	-	(0.02)	(0.00)	(0.02)
11	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58
12	Other equity (revaluation reserve : Rs. Nil)				20,351.17
13	Earnings per share (face value of Rs. 10/- each) (not annualised for the quarters) (Rs.)				
	Basic	(0.38)	1.01	0.18	2.50
	Diluted	(0.38)	1.01	0.18	2.50

Notes :

1) The above unaudited consolidated financial of ZIM Laboratories Limited ('the Parent' or 'the Company') and its subsidiaries (together referred to as 'Group') were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 07 August 2025. The above results have been subjected to limited review by Statutory Auditor of the Parent.

2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).

3) The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures for the year ended 31 March 2025 and the unaudited year to date figures upto 31 December 2024.

4) The consolidated financial results of the Group for the quarter and year ended 31 March 2025 and quarter ended 30 June 2024 were reviewed/audited by another auditor, who expressed an unmodified conclusion/opinion on those results on 20 May 2025 and 03 August 2024 respectively.

5) The Board of Directors of the Parent on 04 August 2025 have approved the closure of ZIM Laboratories Middle East DMCC, Step Down Subsidiary, subject to the approval of relevant regulatory authorities.

6) The Group is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments.

Place: Nagpur
Date: 07 August 2025

ANWAR
SIRAJ DAUD

Anwar S. Daud
Managing Director

Digitally signed by ANBAR SRAU DAUD
DN: c=IN, postalCode=400002, st=MAHARASHTRA,
street=NAUGPROPOSTICE HUSAWAIA HIGH SCHOOL SHAN-
NAGADADAU COMPOUND 440032, o=ANAPUR, ou=Personal,
serialNumber=3c356b7d3bf8e1f93cf8be73ebbc5ddac-
58fc4db87312ec2dab6bb6c,
provisionedBy=99162021209115943966,
2.5.4.20=51f2503258d3adab12323cd68fe7de7ff6dfafcb-
73707dc2e3d789f932, email=ANBARDAUD@ZMAIL.IN
Date: 2006.09.07 13:05:30 +05'30'

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZIM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **ZIM LABORATORIES LIMITED** ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The standalone financial results of the Company for the quarter and year ended March 31, 2025 and the quarter ended June 30, 2024 included in the Statement, were reviewed/ audited by another auditor who expressed an unmodified conclusion/opinion on those statements on May 20, 2025 for the quarter and year ended March 31, 2025 and August 3, 2024 for the quarter ended June 30, 2024.

Our conclusion on the statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Viral
Rajnikant
Shah

Digitally signed
by Viral Rajnikant
Shah
Date: 2025.08.07
13:54:26 +05'30'

Viral R. Shah
Partner

Membership No. 117654
UDIN:25117654BMLLNH6096

Place: Nagpur
Date: August 7, 2025



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India

CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2025

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		(Unaudited)	(Unaudited) Refer Note 3 & 4	(Unaudited) Refer Note 4	(Audited) Refer Note 4
1	Income				
	a) Revenue from operations	7,142.77	10,851.51	8,200.41	37,563.55
	b) Other income	147.56	155.44	98.03	562.09
	Total income	7,290.33	11,006.95	8,298.44	38,125.64
2	Expenses				
	a) Cost of materials consumed	2,761.73	4,860.09	3,100.93	15,500.40
	b) Purchases of stock-in-trade	159.30	329.59	265.74	1,157.82
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	79.86	(364.14)	314.37	126.65
	d) Employee benefits	1,357.42	1,532.91	1,348.05	5,640.62
	e) Finance costs	330.35	290.92	285.75	1,138.58
	f) Depreciation and amortisation	478.98	523.37	491.60	1,989.14
	g) Other expenses	2,350.98	2,969.36	2,383.58	10,811.22
	Total expenses	7,518.62	10,142.10	8,190.02	36,364.43
3	Profit /(loss) before tax (1-2)	(228.29)	864.85	108.42	1,761.21
4	Tax expense /(credit)				
	Current Tax	-	334.20	21.00	444.69
	Deferred Tax	(59.10)	(11.43)	11.52	142.12
	Total tax expense	(59.10)	322.77	32.52	586.81
5	Profit /(loss) after tax (3-4)	(169.19)	542.08	75.90	1,174.40
6	Other comprehensive income - profit/(loss)				
	a) Items that will not be reclassified to profit or loss	(18.99)	(35.54)	(13.47)	(75.95)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	5.53	10.35	3.92	22.11
	Other comprehensive income (net of tax) - profit/(loss)	(13.46)	(25.19)	(9.55)	(53.84)
7	Total comprehensive income (5+6)	(182.65)	516.89	66.35	1,120.56
8	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58
9	Other equity (revaluation reserve : Rs. Nil)				19,578.80
10	Earnings per share (face value of Rs. 10/- each) (not annualised for quarters) (Rs.)				
	Basic	(0.35)	1.11	0.16	2.41
	Diluted	(0.35)	1.11	0.16	2.41

Notes :

- 1) The above unaudited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 07 August 2025. The above results have been subjected to limited review by Statutory Auditor of the Company.
- 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures for the year ended 31 March 2025 and the unaudited year to date figures upto 31 December 2024.
- 4) The standalone financial results of the Company for the quarter and year ended 31 March 2025 and quarter ended 30 June 2024 were reviewed/audited by another auditor, who expressed an unmodified conclusion/opinion on those results on 20 May 2025 and 03 August 2024 respectively.
- 5) The Company is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments.

Place: Nagpur
Date: 07 August 2025

ANWAR
SIRAJ DAUD

Digitaly signed by ANWAR SIRAJ DAUD
DN: cn=ANWAR SIRAJ DAUD, o=ANWAR SIRAJ DAUD, email=ANWAR.SIRAJ.DAUD@ANWAR.SIRAJ.DAUD, ou=ANWAR SIRAJ DAUD, c=IN

Anwar S. Daud
Managing Director

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023

Annexure- I

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Protiviti India Member Private Limited as Internal Auditor of the Company for the F.Y. 2025-26 as per Section 138 of the Companies Act, 2013.
2.	Date of appointment/ re-appointment/cessation and Term of appointment/ re-appointment	The date of appointment of Protiviti India Member Private Limited as Internal Auditor of the Company for the F.Y. 2025-26 is 07 th August, 2025.
3.	Brief profile (in case of appointment)	<p>Protiviti India Member Private Limited (Protiviti) is a global consulting which provides services in the areas such as internal audit, technology, digital, business process, analytics, risk, compliance and transactions.</p> <p>Protiviti has extensive experience in internal audit and Internal Financial Controls reviews. It has been conducting the Internal Audit of the Company since F.Y. 2019-20.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

ZIM LABORATORIES LIMITED

Annexure II

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: ZIM Scientific Office L.L.C. The Company was incorporated in November 2024. Turnover: NIL
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	The transaction of investment in share capital of ZIM Scientific Office L.L.C, Step-down Subsidiary of the Company by ZIM Laboratories FZE, Wholly Owned Subsidiary of the Company is a related party transaction and is at arms length. Mr. Zulfiquar Kamal, one of the Promoters of the Company is appointed as Director on the Board of ZIM Scientific Office L.L.C.
3	Industry to which the entity being acquired belongs	Pharmaceutical
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment in share capital of ZIM Scientific Office L.L.C, Step-down Subsidiary is with an objective of expansion and development of business in the GCC region.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition	2-3 months from the date of transfer of funds (investment in the share capital)
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired	ZIM Laboratories FZE, Wholly Owned Subsidiary of the Company will invest upto AED 4,50,000 in the share capital of

ZIM LABORATORIES LIMITED



Zeal & Innovation in Medicine

		ZIM Scientific Office L.L.C, Step-down Subsidiary.
9	Percentage of shareholding /control acquired and / or number of shares acquired	With the proposed investment, the shareholding of ZIM Laboratories FZE, Wholly Owned Subsidiary in ZIM Scientific Office L.L.C, Step-down Subsidiary remains at 100%.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>ZIM Scientific Office L.L.C, Step-down Subsidiary was incorporated in Dubai, UAE in November, 2024 to operate in Pharmaceutical Industry.</p> <p>The turnover of the company since incorporation is NIL.</p>

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.7118.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

Annexure III

Sr. No.	Particulars	Remarks
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Nil
2	Date on which the agreement for sale has been entered into	Not Applicable
3	The expected date of completion of sale/disposal;	The closure may be subject to the timeline as may be stipulated by the UAE regulatory authorities.
4	Consideration received from such sale/disposal	Not Applicable
5	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Not Applicable
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	Not Applicable
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not Applicable
8	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not Applicable

ZIM LABORATORIES LIMITED